ERBB2 and breast cancer: Hence, insulin-like growth factor 1 receptor (IGF1R) inhibition by cixutumumab has been tested in combination with lapatinib plus capecitabine in locally advanced or metastatic HER2 BC resistant to trastuzumab, but with poor results (NCCTG N0733 and NCT00684983 [171]).